VANI

1.1404.59%
DM

Daniel Mark Bradbury

Independent Chairman of the Board

Mr. Daniel Mark Bradbury, also known as Dan, is Chairman of the Board of Tavo Biotherapeutics, Inc. Mr. Bradbury has been an Independent Director of Biocon Biologics Limited since 2019. Mr. Bradburyis Chairman of the Board of Persephone Biosciences, Inc. from 2024. He also serves as Chairman of the Board at Biolinq Incorporated and serves as its Director. He has been an Independent Director at Panacea Acquisition Corp and served as its Independent Chairman of the Board since 2020. He was Advisor at Vivani Medical, Inc. until 2024 and serves as its Independent Director since March 2024. He serves as Board Observer at NeuraLace Medical, Inc. since January 2023. Mr. Bradbury was Executive Chairman of Equillium, Inc. from January 01, 2020 to October 1, 2025 and was its Chief Executive Officer. Mr. Bradbury is Chairman of the Board of Equillium, Inc. from October 1, 2025. He served as Independent Non-executive Director of Biocon Limited since April 25, 2013 until July 2022 and also serves as Independent Director since September 2026. He served as a Director of IQHQ, Inc. He serves as Director at AltHeadx, Inc. since 2021. He had been Chairman of Equillium, Inc. since June March 2017 until December 2019 and served as Chief Executive Officer since June 01, 2018 until December 2019 and as President from March 2017 until June 2018. Mr. Bradbury serves as Chairman of the Board at DiaVacs, Inc. Mr. Bradbury serves as a Vice President of BIOCOM, Inc. He is a Co-Founder of Sensulin, LLC. Since May 2017. Mr. Bradbury has extensive experience in pharmaceutical industry strategy, operations and management. Mr. Bradbury is the Founder of BioBrit, LLC and serves as its Managing Member since September 2012. He had been Director of Alume Biosciences, Inc. since September 2020 until December 2025 and serves as Executive Chairman from December 2025. He is a life sciences executive with experience in creating transformative business strategies, bringing novel medicines to market and maximizing shareholder value. Mr. Bradbury served as the President at Amylin Pharmaceuticals, LLC from June 2006 to March 2007 and served as its Chief Executive Officer from March 1, 2007 to August 2012, Chief Operating Officer from June 2003 to June 2006, Executive Vice President from June 2000 to June 2003, Senior Vice President of Corporate Development from April 1998 to June 2000 and Vice President of Marketing from June 1995 to April 1998. From July 1994 to May 1995, he served as Director of Marketing at Amylin Europe Limited. Prior to Amylin, Mr. Bradbury was employed at SmithKline Beecham Pharmaceuticals from September 1984 to July 1994, where he served a number of positions in international sales and marketing, including Associate Director, Anti-Infectives in the Worldwide Strategic Product Development Division. He served at SmithKline Beecham Limited. He serves as Chairman of the Board at Sensulin, LLC. He has been the Chairman of Liquid Grids, Inc. since May 13, 2014 and Sinocare Meditech (formerly known as Freedom Meditech, Inc.) since September 2014. He was the Chairman at Thesan Pharmaceuticals, Inc. since July 19, 2016. He has been Independent Chairman of the Board at Castle Biosciences, Inc. since September 2014 and is its Director since September 2012. He serves as the Chairman of Advisory Council at the Keck Graduate Institute of Applied Life Sciences. He had been an Independent Director of Intercept Pharmaceuticals, Inc. since July 19, 2016 and also served as its Independent Chairman since October 2023. He served as Non-Executive Independent Director of Syngene International Ltd. from July 24, 2013 to May 15, 2016. He served as a Director at Renova Therapeutics Inc. since November 2014. He was Independent Director of Geron Corporation from 2012 to June 15, 2019. He served as a Director of BioMed Realty Trust Inc. since January 4, 2013 until January 2016. He serves as a Director of Cerexa, Inc, DiaVacs, Inc. Sensulin, Inc. BIOCOM, Inc. and Pharmaceutical Research and manufacturers of America (PhRMA) and served as Director at Microdermis Corporation (Microdermis, Inc.). He has been a Director at Peninsula Pharmaceuticals, Inc. since December 2003. He served as an Independent Director of Corcept Therapeutics Incorporated since October 15, 2012 until June 18, 2019. He has been an Independent Director of Biocon Limited since April 25, 2013. He has been a Director of ProSciento, Inc. since November 2013. He serves as a Member of Advisory Board at MD Revolution, Inc. He serves as a Member of Advisory Board of Patricia Industries (formerly known as Investor Growth Capital) and is responsible for biotechnology and pharmaceutical development. He served as an Independent Director of Novacea, Inc. since September 2005 and its Lead Director since December 2007. Mr. Bradbury served as a Director of Amylin Pharmaceuticals, LLC from June 2006 to August 2012. He serves as a Member of Advisory Board at AmideBio, LLC. He also serves as an advisory Board Member for the University of California San Diego. He serves as a Member of Advisory Council at The Rady School of Management at the University of California, San Diego. He served as an Independent Director of Illumina Inc. since January 9, 2004 until May 29, 2017. He is a Director of Abilita Therapeutics, Inc. Mr. Bradbury is also a Member of the Board of trustees of the Keck Graduate Institute. He is a Member of RAND Health Board of Advisors and University of Miami's Innovation Corporate Advisory Council. He has been honored with the San Diego American Diabetes Association's Father of the Year Award (2011), the Corporate Directors Forum Director of the Year Award for Enhancing Economic Value (2012) and was Ernst & Young's Entrepreneur of the Year Finalist (2012). He serves as Director of Synedgen, Inc. He is a Member of the Royal Pharmaceutical Society of Great Britain. Mr. Bradbury completed the Director Certification Program at the University of California, Los Angeles (2004) and the International Executive Program from INSEAD, European Institute of Business Administration, France (1994). He holds a B. Pharm (Hons.) from Nottingham University, UK in the year 1980-1983 and a Diploma in Management Studies from the University of West London in the United Kingdom and Diploma of the Chartered Institute of Marketing (DCIM) from Harrow and Ealing Colleges of Higher Education, UK in 1985. He served as Chief Executive Officer of Equillium until January 2020. During his 18-year tenure at Amylin, the company launched three first-in-class medicines, including the first once-a-week therapy to treat diabetes and was listed on the Nasdaq 100. He served as Amylin’s Chief Executive Officer from March 2007 until its acquisition by Bristol-Myers Squibb Company in August 2012. Dan is the Executive Chairman and Co-Founder of Equillium, Inc. (NASDAQ: EQ), a publicly traded biopharmaceutical company based in La Jolla, CA, focused on developing products to treat severe autoimmune and

公司職務